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One sentence summary: Parasitism of bacteria (Escherichia coli) by viruses can be prevented by compounds present in the natural environment of this
species, but antibiotics do not show the same effects.
Editor: Kornelia Smalla
ABSTRACT
Although experiments indicate that the abiotic environment plays an important role in bacterial interactions with their
parasitic viruses (bacteriophages or phages), it is not yet clear how exposure to compounds present in nature alters the
impact of phages on bacterial growth and evolution. To address this question, we exposed Escherichia coli K12 MG1655, in
combination with three lytic phages, to various substances that natural and clinical microbial populations are likely to
encounter: bile salts (present in mammalian gastrointestinal tracts), sodium dodecyl sulfate (SDS, a common surfactant
in cleaning and hygiene products) and four antibiotics (present at variable concentrations in natural and clinical
environments). Our results show that bile salts and SDS can reduce the detrimental effect of phages on bacterial growth.
In some cases these compounds completely mitigated any negative effects of phages on bacterial growth and consequently
bacteria did not evolve resistance to phages in these conditions. The proportional effects of phages were unaffected by
antibiotics in most combinations, excepting three cases of phage-drug synergy. These results suggest that accounting for
interactions between phages and environmental factors such as surfactants and antibiotics will improve understanding
of both bacterial growth and resistance evolution to phages in vivo and in nature.
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INTRODUCTION
Bacteria–phage interactions, including those relevant to phage
therapy (Sulakvelidze, Alavidze and Morris 2001; Abedon et al.
2011), have been studied intensively and successfully in vitro
(Kutter and Sulakvelidze 2004; Calendar andAbedon 2006). How-
ever, the majority of experiments have used a single set of sim-
plified experimental conditions, which is in stark contrast to the
complexity of natural microbial ecosystems. In such communi-
ties, bacteria and phages grow and evolve in chemically com-
plex environments, making it difficult to measure the relative
effects of different variables on phage infection and bacterial
growth and evolution. Consequently, it is not known how envi-
ronmental factors that natural and clinical populations are ex-
posed to modify the bacteria–phage/host–parasite interactions
that have been observed in vitro. One possibility is that com-
pounds present outside the laboratory increase or decrease the
impact of phages on bacterial population growth, and conse-
quently the likelihood of bacteria evolving resistance to phages,
compared to what we would predict from in vitro observations
in a single set of conditions. We aimed to test this for Escherichia
coli (strain K12MG1655) exposed to lytic phages in a standard ex-
perimental environment (nutrient broth at 37◦C) in the presence
Received: 20 April 2016; Accepted: 10 October 2016
C© FEMS 2016. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
1
2 FEMS Microbiology Ecology, 2017, Vol. 93, No. 1
and absence of chemical compounds representing some realis-
tic aspects of natural and clinical environments.
Escherichia coli is a key member of the human gut micro-
biota and the gut microbiota of many other warm-blooded ani-
mal hosts (Gordon and Cowling 2003). Althoughmost strains are
gut commensals, some cause common and diverse infections
(Kaper, Nataro and Mobley 2004; Tenaillon et al. 2010). Antibi-
otic resistance is a major problem in this species (World Health
Organization 2014), and phage therapy has been proposed as an
adjuvant or alternative solution (Bru¨ssow 2005; Kutter et al. 2010;
Viertel, Ritter and Horz 2014). We hypothesized that chemicals
such as bile salts, which are present in the mammalian gas-
trointestinal tract, can either increase or decrease the effect of
phages on E. coli population growth observed in standard lab-
oratory media. Bile salts are secreted into the small intestine,
reaching variable final concentrations (0.2%–2% bile acid; Hof-
mann 1998; Gunn 2000) and promoting solubilization of fatty
molecules due to detergent-like properties. Crucially, bile salts
can affect a wide range of bacterial traits (Gunn 2000; Begley,
Gahan and Hill 2005), some of which may be involved in in-
teractions with phages (Baucheron et al. 2004; Pumbwe et al.
2007; Reen et al. 2012; Hamner et al. 2013). Indeed, bile salts are
known to alter phage adsorption and plaque formation (Gabig
et al. 2002), although whether this also affects bacterial growth
in the presence of phages in liquid culture or the evolution of
resistance to phages is not clear.
Because bile salts are surfactants that can inhibit bacte-
rial population growth (Begley, Gahan and Hill 2005), we also
tested whether a different surfactant, sodium dodecyl sulfate
(SDS), would have similar effects. This is important to determine
whether effects observed for bile salts are conserved across
other surfactants, but also because SDS is an ingredient in awide
range of cleaning, cosmetic and hygiene products. Bacteria and
phages are therefore likely to encounter variable SDS concentra-
tions through exposure to products containing SDS (concentra-
tions vary widely from <3% in hygiene products such as tooth-
paste (Neppelberg et al. 2007) to more than 30% in some cleaning
and cosmetic products (Bondi et al. 2015)) and in wastewater re-
sulting from their use (Singer and Tjeerdema 1993). To deter-
mine whether observed effects were specific to surfactants or
also extended to other growth-inhibiting compounds, we tested
the additional hypothesis that growth inhibition by antibiotics
has similar effects on bacteria–virus interactions compared to
equivalent concentrations of bile salts or SDS. This hypothesis
is also relevant to both phage therapy and antibiotic treatment,
because phage–antibiotic interactions can potentially increase
or decrease the effectiveness of antibiotic or phage+antibiotic
treatments (Comeau et al. 2007; Ryan et al. 2012; Knezevic et al.
2013; Kamal and Dennis 2015). Such interactions could come
about through effects of antibiotics on cellular processes in-
volved in phage infection or replication, or trade-offs among
resistance mechanisms (Chan et al. 2016; Torres-Barcelo´ and
Hochberg 2016), although these effects are likely to vary among
antibiotics. We therefore included four different antibiotics.
For three different bacteriophages (representing the three
Caudovirales families), we tested for non-multiplicative interac-
tions with bile salts, SDS and four different antibiotics in terms
of their effects on bacterial growth. That is, we measured the ef-
fect of each phage independently and in combination with mul-
tiple concentrations of each compound. We also measured the
effect of each concentration of each compound in the absence
of phages, before quantifying the deviation of bacterial growth
in combination treatments from what we would expect if each
phage or compound caused the same proportional change in
bacterial growth as it does on its own. We employed the same
statistical framework to quantify these interactions as has been
used previously to infer drug–drug interactions and epistasis
(Trindade et al. 2009; Yeh et al. 2009; Hall and MacLean 2011).
We also tested whether our observations could be explained by
effects of bile salts or SDS on phage survival outside the host,
cation chelation or bacterial autoaggregation (Gabig et al. 2002).
MATERIALS AND METHODS
Organisms and growth conditions
We grew Escherichia coli K12 MG1655 at 37◦C in 100 μL Luria-
Bertani broth supplemented with 10 mMMgSO4 and 10 mM Tris
(hereafter referred to as LB) in flat-bottomed 96-well microplates
in all experiments unless otherwise stated.
In experiments with bile salts, LB was supplemented with
Difco Bile Salts No. 3 (Becton Dickinson, Franklin Lakes, NJ,
USA). In experiments with antibiotics, we used drugs from
four different classes that are associated with different resis-
tance mechanisms (Walsh 2000; Blair et al. 2014) and include
some of the most widely used antibiotics as well as some of
the principal classes used to treat E. coli infections (Johnson
et al. 2006; World Health Organization 2015): chloramphenicol,
ciprofloxacin, streptomycin and tetracycline. In experiments be-
low, we included each antibiotic at a range of concentrations in-
cluding those that inhibit but do not prevent bacterial growth,
and those that prevent growth completely.
We used three lytic phages from different families: λ
(Siphoviridae), T4 (Myoviridae) and T7 (Podoviridae). The λ virus
we used is an obligately lytic mutant called cI26 (Meyer et al.
2012). These phages are phylogenetically and morphologically
distinct, bind to different receptors [LamB (Berkane et al. 2006),
OmpC and LPS (Yu and Mizushima 1982), and LPS (Qimron et al.
2006), respectively] and include some of themost important can-
didates for phage therapy of E. coli infections (Chibani-Chennoufi
et al. 2004; Bru¨ssow 2005). We prepared stocks of each phage by
picking plaques into exponentially growing 5 mL cultures of the
wild-type host bacterium in LB, incubating at 37◦C until lysis
was visible relative to a phage-free control, then removing bac-
teria by adding 10% chloroform, vortexing for 1 min, centrifug-
ing for 3 min and storing lysates at 4◦C. We then diluted these
stocks with LB before adding them to experimental cultures as
described below.
Growth experiments
Every growth experiment was inoculated from an independent
overnight bacterial culture by 800-fold dilution, followed by 1 h
of growth before addition of phages (∼500 particles of λcI26,
T4 or T7 suspended in 10 μL LB or 10 μL sterile LB for phage-
free treatments). For every growth experiment, we quantified
the change in bacterial population density over 24 h by measur-
ing the change in optical density (OD) at 600 nm in a M2 Spec-
traMax Spectrophotometer (Molecular Devices, Sunnyvale, CA,
USA), calculating the growth score OD, equal to OD24h − OD0h,
for each microplate well. This measure has been shown previ-
ously to detect fine-scale variation of bacterial susceptibility to
viruses and viral capacity for infection (Poullain et al. 2008; Hall,
Scanlan and Buckling 2011). We ran eight replicate growth ex-
periments in the presence and absence of each phage at three
concentrations of bile salts, SDS and each antibiotic, plus unsup-
plemented LB. Bile salt and antibiotic experiments were done
in the same temporal block, including the phage and no-phage
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treatments; SDS was tested separately in the presence of each
phage alongside independent control populations (phage-free
and SDS-free treatments). To avoid plate-to-plate or well-to-well
variation influencing our results, we assayed the eight replicates
for each treatment combination in separate microplates and in
different well positions within each microplate in the main ex-
periment; the SDS assay block was smaller and only covered
two microplates, so here we included the same number of repli-
cates for each treatment on both plates and in different well
positions.
Statistical analysis of variation in bacterial
population growth
To determine whether the combined effects of phages and bile
salts, SDS or antibiotics (hereafter referred to as ‘supplements’)
deviated from what we would expect based on their indepen-
dent effects, we compared observed scores to a null model of
multiplicative effects. This ismathematically identical to a com-
mon approach for inferring epistatic interactions among genes
or mutations (e.g. Phillips 2008; Trindade et al. 2009; Hall and
MacLean 2011), and has also been used to identify interactions
among pairs of antibiotics (Yeh et al. 2009). Under thismodel, the
expected effect of a combination of a phage and a supplement
at a given concentration is equal to the product of their indepen-
dent effects on bacterial growth. Thus, for a given combination
of phage × supplement × concentration, our null expectation is
that
ODPS = ODps × ((ODPs/ODps) × (ODpS/ODps)) ,
where subscripts denote the absence and presence of phage and
supplement at a given concentration (p/P for phage and s/S for
supplement, with capital letters indicating presence and lower-
case letters for absence). We can abbreviate this as
WPS = WpSWPs,
where W expresses OD as a fraction of ODps. We tested the
significance of deviations from the expected values using prop-
agation of errors: following Silva et al. (2011) and Trindade et al.
(2009), deviation from the null model (WPS –WpSWPs) has the er-
ror term
√
σWPS2 + σWpS2WPs2 + σWPs2WsP 2,
where σ denotes the standard deviation of the replicated esti-
mates in the corresponding phage-supplement treatment, such
that greater among-replicate variance within the phage, sup-
plement or combination treatment all increase the error term.
We took deviation from the null model as significant when its
squared and rooted value calculated to two decimal places ex-
ceeded the error term.
Testing for phage resistance
In our experimental conditions, bacteria can rapidly evolve re-
sistance to phages (Tazzyman and Hall 2015). We therefore
tested whether the observed effects of bile salts and SDS on
the impact of phage λcI26 on bacterial growth also altered the
frequency of bacterial resistance to phages at the end of 24 h
growth. We did this by testing for phage resistance in each of
six replicate populations grown in the presence and absence of
phage λcI26 in LB, LB + 5000 mg/L bile salts or LB + 300 mg/L
SDS. We chose these concentrations because the growth exper-
iments above indicated that they significantly alter the impact
of phages. For each population, at the end of 24 h growth with
or without phages, we streaked bacteria onto agar plates and
incubated them overnight to obtain single, phage-free colonies.
We then picked 10 colonies at random from each population and
streaked themacross a line of phage λcI26 (20μL containing∼6×
104 phages from stock lysate) that had been dried onto a LB agar
plate. After overnight incubation, we followed previous studies
in scoring colonies as resistant if there was no visible inhibition
of bacterial growth in the segment of the streak that had been
exposed to phage, and sensitive if there was inhibition (Buckling
and Rainey 2002; Brockhurst et al. 2007). We then took the resis-
tance of each population as the fraction of colonies that were re-
sistant, before plotting the resistance of individual populations
from each treatment.
Physiological basis of interactive effects
We tested some of the possible mechanisms explaining ob-
served effects of bile salts and SDS. First, we determined
whether detergents modified phage survival outside the bacte-
rial host. To do this, we used the same conditions described for
our growth experiments and added 5–10 000 phage particles to
bacteria-free LB, LB+bile salts or LB+SDS, incubated for 24 h,
and then counted the plaque-forming units in each population,
with six replicate populations in each treatment, by dilution and
plating onto lawns of E. coli growing in LB agar. Here we tested
each of the three phages at a single concentration of bile salts
and SDS, choosing concentrations that the above experiments
indicated to have representative effects on the impact of phages
(10 000 and 300 mg/L respectively), that is, concentrations that
significantly impacted the ability of phage to reduce bacterial
population growth. We then tested for differential survival of
each phage in the presence of each surfactant relative to the
control using t-tests, accepting significance only after sequential
Bonferroni correction for multiple testing. Second, because pre-
vious research suggests that bacterial aggregation can increase
susceptibility to phage infection (Gabig et al. 2002; Kirby 2012),
we tested whether bile salts or SDS altered autoaggregation in
our experimental conditions by the same methods described by
Gabig et al. (2002) and Hasman, Chakraborty and Klemm (1999):
we grew three replicate 10 mL cultures of the wild type in LB
or LB supplemented with bile salts or SDS, before leaving them
unshaken and sampling 1 cm below the meniscus periodically,
measuring OD600 of each sample immediately and following
the rate of sedimentation by the drop in OD scores over time.
We then used one-way analysis of variance (ANOVA) to test for
variation of the change in OD after 158 and 331min among treat-
ments (bile salts, SDS or unsupplemented LB). Third, because
cations, specifically Mg2+, are required for λcI26 infections, de-
tergents could potentially modify phage infection by chelating
cations and preventing adsorption (Gabig et al. 2002). We there-
fore testedwhether supplementationwith additionalMgSO4 (10,
20 or 40 mM added at the start of the 24 h growth experiment)
restored λcI26 infection in the presence of bile salts and SDS
(10 000 and 300 mg/L). We determined whether MgSO4 altered
the effect of phage in the bile and SDS treatments by the signif-
icance of the interaction term in two-way ANOVA with MgSO4
concentration and phage (presence or absence) as factors.
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Figure 1. Growth of E. coli at various concentrations of (A) bile salts or (B) SDS in
the presence and absence of three different phages. Each bar shows the average
± SE from eight replicate populations, with growth measured as the change in
optical density over 24 h. Asterisks indicate values that deviate significantly from
a null prediction based on the independent effects of phages and either bile salts
or SDS, as described in the main text and defined by Trindade et al. (2009) and
Silva et al. (2011).
RESULTS
Bile salts and SDS buffer the effects of some phages
In the presence of phage λcI26, Escherichia coli population densi-
ties were significantly greater than those predicted by our null
model at all three bile salt concentrations (Fig. 1A), and not sig-
nificantly different frombacterial densities observed at the same
concentrations in the absence of phages (t-tests: P > 0.2 in each
case). In other words, bile salts prevented phage λcI26 from re-
ducing bacterial population growth. Although bacterial growth
was also slightly higher than expected in the presence of phage
T4 at the highest concentration of bile salts, bile salts had little
impact on growth reduction due to phages T4 and T7 (Fig. 1A),
both ofwhich had stronger effects on bacterial growth in general
compared to λcI26.
The other surfactant in our experiment, SDS, also prevented
phage λcI26 from reducing bacterial population growth, which
was significantly greater than that predicted by our null model
at both of the two highest SDS concentrations (Fig. 1B). As ob-
served for bile salts, at these concentrations there was no sig-
nificant effect of phage λcI26 on bacterial growth (t-tests: P >
0.3 in both cases). A similar effect was observed for SDS with
phage T7 (Fig. 1B), although phage action was completely pre-
vented only at the highest concentration (t-test comparing with
and without phage at 300 mg/L: P = 0.02; 1000 mg/L: P = 0.60).
SDS did not prevent T4 from reducing bacterial growth at any of
the concentrations tested (Fig. 1B).
The impact of bile salts and SDS on the reduction in bacterial
growth caused by phage λcI26 was also visible in growth curves
over 24 h (Fig. S1, Supporting Information) and in a separate
experiment where we estimated bacterial population densities
fromplating and colony-forming unit counts (Fig. S2, Supporting
Information).
Antibiotics and phages interact approximately
multiplicatively in most cases
The combined effects of antibiotics and phages on bacterial
growth did not significantly deviate from that predicted by their
independent effects in 33 out of 36 treatments. In the remain-
ing three treatments, observed growth was lower than expected
(3 mg/L chloramphenicol+λcI26; 0.02 mg/L ciprofloxacin+λcI26;
5 mg/L tetracycline+λcI26; Fig. 2A, B and D), although in each of
these cases the deviation from our null expectation was small.
Bile salts and SDS prevent resistance evolution
Having found that both bile salts and SDS could prevent phage
λcI26 from reducing bacterial growth in liquid culture, we next
tested whether this leads to a concomitant decrease in the like-
lihood that bacteria evolve phage resistance. We found that
populations of E. coli that were exposed to phage λcI26 in LB con-
sistently evolved resistance to this phage (Fig. 3A). By contrast,
populations that were exposed to both phage λcI26 and either
bile salts or SDS never evolved resistance to phage λcI26 (Fig. 3B
and C), as observed for populations that were never exposed to
phages in the same experiment.
Extra-host survival varies among phages and
environments
Bile salts had no effect on survival of λcI26 in the absence of
bacteria (t-test comparing LB to LB+bile salts: t10 = 1, P = 0.34;
Fig. 4) or T4 (t10 = 0.4, P = 0.67), but reduced T7 survival by 36%
on average (t10 = 3.8, P = 0.003). SDS had no effect on T4 survival
(t10 = 0.78, P = 0.45), but significantly reduced both λcI26 and
T7 survival (Welch’s t-tests assuming unequal variances: t5 =
14.4, P = 0.0001 and t5 = 10.5, P = 0.0001 respectively). No viable
λcI26 particles were detected following treatment with SDS and
T7 survival was reduced by 89% compared to unsupplemented
LB on average. Thus, prevention of λcI26 and T7 infection in the
presence of SDS can be at least partially explained by the effects
of SDS on free phage particles. By contrast, the effect of bile salts
on λcI26 infection in liquid culture does not seem to be associ-
ated with reduced survival of free phage particles.
Detergents affect bacterial autoaggregation
Escherichia coli sedimented in unshaken cultures relatively
rapidly in LB, but less rapidly in LB supplemented with bile
salts or SDS: OD600 just below the meniscus decreased relatively
quickly in unsupplemented LB (Fig. 5; one-way ANOVA for vari-
ation among treatments of the change in OD after 158 min:
F2,6 = 12.77, P = 0.007; pairwise Tukey tests show LB is signifi-
cantly lower than LB+bile or LB+SDS), although by the end of
the experiment the cultures in LB+bile salts had also partially
sedimented (variation among treatments after 331 min: F2,6 =
47.63, P = 0.0002; pairwise Tukey tests show LB and LB+bile are
significantly lower than LB+SDS). The relatively rapid sedimen-
tation in LB was also observable by eye (Fig. S3, Supporting In-
formation). Despite this, microscopy showed no clear difference
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Figure 2. Growth of E. coli at various concentrations of four antibiotics: (A) chlo-
ramphenicol, (B) ciprofloxacin, (C) streptomycin, (D) tetracycline. Populations
were grown in the presence and absence of all three phages (x-axis). Each bar
shows the average ± SE from eight replicate populations. Asterisks indicate val-
ues that deviate significantly from a null prediction based on the independent
effects of phages and either bile salts or SDS, as in Fig. 1.
in cell size, shape or spatial organization among treatments
(Fig. S4, Supporting Information).
Cation supplementation does not restore phage
infection
Increasing the concentration of MgSO4, which is required by
λcI26 for infection of E. coli K12 MG1655, did not restore the neg-
ative effect of this phage on bacterial growth in the presence of
bile salts (MgSO4 concentration × phage interaction in two-way
ANOVA: F2,18 = 2.69, P = 0.09; Fig. S5, Supporting Information) or
SDS (F2,18 = 2.17, P = 0.14; Fig. S5), which does not support the
hypothesis that Mg2+ chelation by bile salts causes the reduced
impact of phages on bacterial growth observed in these treat-
ments. Increasing MgSO4 concentration over this range (10–40
mM) did not alter the effect of phage λcI26 in the absence of bile
salts either (F2,18 = 1.27, P = 0.31; Fig. S5).
DISCUSSION
Natural and human-associated surfactants altered the ecologi-
cal and evolutionary effects of some of the lytic phages in our
experiment. Specifically, bile salts and SDS reduced the impact
of phage λcI26 on Escherichia coli growth in liquid culture, and
consequently phage-resistant mutants did not spread in these
conditions. These surfactants had weaker effects on the reduc-
tion in bacterial growth caused by the other phages in our exper-
iment. These results indicate that bile salts in the mammalian
intestine, the natural environment for these species, may qual-
itatively change the interaction between E. coli and lambdoid
lytic phages, although the effects of surfactants are likely to vary
among different phages, as they did in our experiments. We also
tested for similar interactions with four antibiotics and found
that antibiotics did not modify phage effects in the same way
as surfactants, ruling out the possibility that effects of surfac-
tants were simply due to inhibition of bacterial growth. We did
however find a few cases of synergy between drugs and phages,
consistent with previous suggestions that phage infection can
boost the efficacy of antibiotics or vice versa (Escobar-Pa´ramo,
Gougat-Barbera and Hochberg 2012; Zhang and Buckling 2012;
Torres-Barcelo´ et al. 2014). On average, phage λcI26 had weaker
effects on bacterial growth in unsupplemented LB compared to
T4 and T7, in line with previously reported variation of adsorp-
tion and replication rates among these phages (De Paepe and
Taddei 2006) and the low phages to bacteria ratio at the start of
the experiment.
Our finding that bile salts reduced the impact of some phages
in liquid culture is consistent with previous observations that
bile salts can inhibit phage adsorption and plaque formation
(Gabig et al. 2002). Those authors found that sensitivity to phage
λwas increased in E. coli expressing Ag43, a phase-variable outer
membrane protein associated with increased autoaggregation
and sedimentation. Consistentwith this, we found that both bile
salts and SDS reduced autoaggregation and sedimentation. This
also supports the earlier observation (Kirby 2012) that aggrega-
tion of Staphylococcus aureus increases susceptibility to phage,
and the notion that clusters of host cells may be relatively sus-
ceptible to phage infection (Abedon 2012).
As well as building on previous work, our results provide
some novel insights: (i) bile salts can completely prevent the
reduction in bacterial growth due to infection by some phages
in liquid culture, thus preventing bacteria from evolving resis-
tance to the respective phage. Impacts on bacterial population
size and resistance are particularly important in the context of
phage therapy where, as with antibiotics, these are key deter-
minants of treatment outcomes (Levin and Bull 2004; Bru¨ssow
2005). (ii) As well as bacterial autoaggregation, bile salts reduced
extra-host survival of one phage (T7), indicating that interac-
tions between phages and other substances can stem from a
combination of physiological changes to both phages and bac-
teria. (iii) SDS had qualitatively similar effects on growth and
resistance compared to bile salts, and even stronger effects
on phage survival; SDS is extremely common in cleaning and
hygiene products and therefore likely to be encountered in vari-
able concentrations by bacteria and viruses outside the labora-
tory, including in human-associated environments such as skin
and the gastrointestinal tract (Singer and Tjeerdema 1993). Our
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Figure 3. Resistance to phage λcI26 in populations grown in the presence or absence of this phage in (A) LB or (B) LB supplemented with 5000 mg/L bile salts or (C) 300
mg/L SDS. Each circle shows the proportion of 10 colonies in a single population that were resistant to phage λcI26, with six independent replicate populations in each
treatment.
Figure 4. Effects of bile salts (10 000 mg/L) and SDS (300 mg/L) on phage survival outside the bacterial host for (A) λcI26, (B) T4 and (C) T7. Each point shows a single
independent population of phages (n = 6 in each treatment) incubated in the same conditions and for the same duration as the main experiment but in the absence
of bacteria. Bars show the mean for each treatment.
finding that SDS is deleterious to phages builds on evidence that
it is an effective antiviral, as suggested by previous work with
herpes simplex type 2 and HIV type 1 (Howett et al. 1999), al-
though we note that those are enveloped viruses and therefore
the antiviral mechanism may be different.
Although the phage–antibiotic interactions we observed
were weaker than those between bile salts or SDS and some
phages, the notion that phage+antibiotic combinations can be
more effective at reducing bacterial growth than we would ex-
pect from their independent effects is potentially important for
both phage and antibiotic therapies. The impact of antibiotics
may be modified by phages that are naturally present in hu-
mans and animals (Breitbart et al. 2003; Ogilvie and Jones 2015),
and combination therapy using phages and antibiotics may be
more or less effective depending on these interactions (Viertel,
Ritter and Horz 2014). In support, analogous interactions be-
tween pairs of antibiotics have been shown to strongly affect
clearance, resistance and optimal dosing in vitro (Hegreness et al.
2008; Pen˜a-Miller et al. 2013; Fuentes-Hernandez et al. 2015).
Moreover, recent work indicates that phage–antibiotic interac-
tions are also prevalent in other bacteria–virus–antibiotic com-
binations (Comeau et al. 2007; Escobar-Pa´ramo, Gougat-Barbera
and Hochberg 2012; Zhang and Buckling 2012; Torres-Barcelo´
et al. 2014; Kamal and Dennis 2015).
One limitation of our approach is that phage–antibiotic syn-
ergy becomes difficult to detect when the phage or antibiotic has
very strong effects independently, because the expected growth
score in the combination treatment is close to zero. Thus, we
cannot rule out additional, undetected phage–drug synergy for
some combinations. However, this would not have prevented us
from detecting antagonistic interactions, as observed with bile
salts and SDS. This was the main reason for including the an-
tibiotic treatments in our growth experiments, which showed
conclusively that the antagonistic interactions between surfac-
tants and phages were not explained by general inhibition of
bacterial growth. An additional limitation is that wewere unable
to detect any change in cell physiology or cell–cell interactions
due to bile salts or SDS by microscopy. It is possible that spatial
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Figure 5. Bacterial autoaggregation in unshaken, phage-free conditions. Each series of lines and points shows an independent E. coli culture in (A) LB, (B) LB supple-
mented with 10 000 mg/L bile salts or (C) LB supplemented with 300 mg/L SDS. At each time point, we sampled each culture from ∼1 cm below the meniscus and
measured OD immediately. Thus, rapid sedimentation leads to a rapid drop in OD shown here.
organization is disrupted during sampling and slide preparation,
and therefore some differences between treatments might only
be resolved using time-lapsemicroscopy ormicrofluidics, which
are beyond the scope of this manuscript. Nevertheless, our ob-
servations did not show any changes, such as filamentation or
chain formation that have been implicated in altered responses
to phages (Kamal and Dennis 2015).
In summary, we found that surfactants can strongly influ-
ence the effect of bacteriophages on bacterial growth and the
spread of resistance to bacteriophages. A key avenue for future
research is determining whether the effects of bile salts or SDS
we observed in vitro are also manifest in the mammalian gas-
trointestinal tract. Realistic bile salt concentrations are likely to
include the range covered by our experiments (Hofmann 1998;
Gunn 2000), and exposure of bacteria and phages to SDS is
probably also common at variable concentrations in nature and
in humans via dermal contact and oral ingestion (Singer and
Tjeerdema 1993). Although physiological effects of bile salts on
bacteria have been observed in vivo (Begley, Gahan and Hill 2005;
Giraud et al. 2008; De Paepe et al. 2011), whether this also affects
phage infection remains to be seen.
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